Management of telaprevir-based triple therapy for hepatitis C virus recurrence post liver transplant

Table 1 Characteristics of patients at baseline

Demography
Age, yr	57	41-70
Gender (male/female)	16/3
Body mass index (kg/m2)	26	21-33
Race, n/%	19	100
Caucasian, n/%	18	94.74
Hispanic, n/%	1	5.26
Immunosuppressive regimen
TAC/CSA	17/2
MMF (n)	8
Steroids (n)	0
Baseline clinical parameters
Duration of therapy	24	4-48
Ishak fibrosis score (grade)	2	0-4
Inflammation (grade)	1.5	0-2
Fibroscan baseline (kPa)	13.8	4.5-46.4
Time from LT to triple therapy (mo)	22	7-295
Baseline clinical chemistry
Bilirubin total (mg/dL)	0.8	0.3-3.2
GGT (U/L)	52	13-32
GPT (ALAT), U/L	41	21-159
GOT (ASAT), U/L	52	18-88
AP, U/L	101	53-404
Creatinine (mg/dL)	1.26	0.67-1.89
GFR (MDRD)	57.3	23-133
International normalized ratio	1	0.8-1.2
Hämoglobin (g/dL)	13.5	9-16.8
WBC (/μL)	3.73	1.6-8.3
Platelet count (/μL)	111	62-246
Basline viral characteristics
HCV GT
1a, n/%	7	36.8
1b, n/%	12	63.2
VL (log10 IU/mL)	1.95	0.13-14.9
Recipient IL-28b polymorphism, n/%
CC	5	26.3
CT	9	47.4
TT	5	26.3
History of any prior PEG-INF/RBV treatment, n/%	11	57.89
History of post-LT PEG-INF/RBV treatment, n/%	5	26.3
HCC prior to LT (n)	6
HBV coinfection (n)	0

TAC: Tacrolimus; HCV: Hepatitis C virus; LT: Liver transplantation; HBV: Hepatitis B virus; GFR: Glomerular filtration rate; WBC: White blood count; GT: Genotype; VL: Viral load; IL-28b: Interleukin-28b; PEG-INF: Pegylated-interferon; RBV: Ribavirine; GGT: Gamma-glutamyl transpeptidase; GPT: Glutamat pyruvat transaminase; ALAT: Alanin-aminotransferase; GOT: Glutamat oxalacetat transaminase; ASAT: Aspartate aminotransferase; CSA: Cyclosporine; MMF: Mycophenolate mofetil; AP: Alkaline phosphatase.